Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers. The company is focusing on the development of the lead product candidate melflufen, a novel lipophilic peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Cytotoxics (PEnC). Melflufen is in development as a new treatment for the hematological cancer multiple myeloma.
Poster presentations at EHA June 14th, 2019
Oncopeptides presents new data at EHA, including updated interim data from the ongoing phase 1/2 ANCHOR study and data from its phase 1/2 O-12-M1 study.
Webcast to review presented data at EHA
Oncopeptides hosted a webcast on Monday, 17 June at 09:00 (CET) to review and update presentations from European Hematology (EHA) meeting. It was presented by CEO Jakob Lindberg and members of the Oncopeptides management team.
Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly cytotoxic payload into myeloma cells through peptidase activity. It belongs to the novel class Peptidase Enhanced Cytotoxics (PEnC), which is a family of lipophilic peptides that exhibit increased activity via peptidase cleavage and have the potential to treat many cancers.
Oncopeptides held an audiocast April 24, 2019, where CEO Jakob Lindberg provided new guidance on the patient recruitment in the OCEAN study and a clinical program update. The webcast was recorded.
Oncopeptides held an operational update on Tuesday, May 21, 2019. It was presented by CEO Jakob Lindberg and members of the Oncopeptides management team. The webcast was recorded.